April 7 (HealthDay News) -- A class of diabetes drugs called glitazones are associated with an increased risk of a vision-threatening complication called diabetic macular edema (DME), which features swelling and fluid accumulation in the retina.
Glitazones are a newer class of diabetes drugs that includes medicines such as pioglitazone (Actos) and rosiglitazone (Avandia).
The U.S. study of 996 DME patients found that those who took glitazones were 2.6 times more likely to develop DME than those who didn't take the drugs. Even after adjusting for other factors, the risk of DME remained 60 percent higher for patients who took glitazones, said the researchers at the Southern California Permanente Medical Group.
The study, published in the April issue of the American Journal of Ophthalmology, isn't the first to suggest a link between glitazones and DME. But it does confirm that the drugs are "modestly associated" with increased risk of DME, which is a common complication of diabetes.
"When treating patients with DME, ophthalmologists should consider the role of the glitazone class of drugs," the study authors concluded.
"Ocular (eye) complications are an overlooked safety issue of systemic drugs," noted Dr. Thomas J. Liesegang, editor-in-chief of the American Journal of Ophthalmology.
"Safety is as important as the efficacy of a drug. However, long-term safety is not currently monitored, because the approval process is based on smaller, shorter-term clinical trials. Safety necessarily requires monitoring of treatment in larger groups of people over longer periods of time. This monitoring is often neglected and should be required of all therapies," Liesegang said.
SOURCE: Elsevier, news release, April 2, 2009